glp-1 long term safety use is no longer a passing trend. Around 11% of US adults now use GLP- 1 medication for weight loss, while approximately 3% of adults in Great Britain reported using it to As GLP-1 receptor agonists continue

Weight-related examples include exploring the potential for GLP-1s: Reduce the risk of cardiovascular events in adults with obesity and cardiovascular disease (CVD) Reduce complications from heart failure, sleep apnea, peripheral artery disease, and non-alcoholic steatohepatitis (NASH) in patients with obesity Researchers are also evaluating the effects of GLP-1s on diabetic retinopathy and even Alzheimers disease

These pouches develop when weakened areas of the colon give way under pressure

Blumenthal, D

It is Copper Tripeptide 3, a specialised copper binding peptide that has attracted interest in hair follicle and skin biology research